Patents by Inventor Mark Murakami

Mark Murakami has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240156816
    Abstract: Described in exemplary embodiments herein are methods, compositions, and kits for diagnosing, prognosing, monitoring, treating and/or preventing a hemopoietic malignancy and/or relapse thereof in a subject. In some embodiments, the methods can include determining an average cellular mass of cells in a sample from the subject and/or detecting one or more molecular signatures in one or more of the cells. In some embodiments, treatment includes administering one or more BCR-ABL tyrosine kinase inhibitors or a pharmaceutical formulation thereof, one or more pre-BCR signaling pathway inhibitors or a pharmaceutical formulation thereof, one or more p38 MAPK inhibitors or a pharmaceutical formulation thereof; or any combination thereof.
    Type: Application
    Filed: December 15, 2023
    Publication date: May 16, 2024
    Inventors: Alexander K. Shalek, Peter Winter, David Weinstock, Mark Murakami, Scott Manalis, Andrew Navia, Jennyfer Galvez-Reyes
  • Publication number: 20240117440
    Abstract: The invention provides a molecular classifier and a targeted sequencing assay for use in characterization and treatment of diffuse large B-cell lymphoma.
    Type: Application
    Filed: September 15, 2023
    Publication date: April 11, 2024
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Bjoern CHAPUY, Donald STEWART, Tim WOOD, Margaret SHIPP, Gad GETZ, Mark MURAKAMI, Lee LAWTON, Andrew DUNFORD, Kirsty WIENAND
  • Publication number: 20240052428
    Abstract: The invention provides compositions and methods useful in characterizing and/or treating classical Hodgkin's Lymphoma and/or primary mediastinal B-cell lymphoma (PMBL). In embodiments, the characterization is carried out using a biological sample comprising circulating tumor DNA (ctDNA) from a subject.
    Type: Application
    Filed: September 15, 2023
    Publication date: February 15, 2024
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Margaret SHIPP, Gad GETZ, Bjoern CHAPUY, Kirsty WIENAND, Donald STEWART, Andrew DUNFORD, Mark MURAKAMI, Lee LAWTON
  • Patent number: 11844800
    Abstract: Described in exemplary embodiments herein are methods, compositions, and kits for diagnosing, prognosing, monitoring, treating and/or preventing a hemopoietic malignancy and/or relapse thereof in a subject. In some embodiments, the methods can include determining an average cellular mass of cells in a sample from the subject and/or detecting one or more molecular signatures in one or more of the cells. In some embodiments, treatment includes administering one or more BCR-ABL tyrosine kinase inhibitors or a pharmaceutical formulation thereof, one or more pre-BCR signaling pathway inhibitors or a pharmaceutical formulation thereof, one or more p38 MAPK inhibitors or a pharmaceutical formulation thereof; or any combination thereof.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: December 19, 2023
    Assignees: Massachusetts Institute of Technology, Dana-Farber Cancer Institute, Inc.
    Inventors: Alexander K. Shalek, Peter Winter, David Weinstock, Mark Murakami, Scott Manalis, Andrew Navia, Jennyfer Galvez-Reyes
  • Publication number: 20220011296
    Abstract: Aspects of the application relate to methods and systems for evaluating treatment response by measuring treatment-induced changes at the single cell level. The disclosure provides methods for isolating single cells that are primary cancer cells, including primary cancer cells from solid tumors, and detecting in minutes to hours from their removal from the body the response of such cells to anti-cancer agents such as radiation, small molecules, biologies, DNA damaging agents and the like.
    Type: Application
    Filed: November 14, 2019
    Publication date: January 13, 2022
    Applicants: Dana-Farber Cancer Institute, Inc., Massachusetts Institute of Technology
    Inventors: Keith Ligon, Seth William Malinowski, Scott R. Manalis, Selim Olcum, Robert J. Kimmerling, Nicholas L. Calistri, David Weinstock, Mark Murakami, Mark M. Stevens
  • Publication number: 20210128557
    Abstract: Described in exemplary embodiments herein are methods, compositions, and kits for diagnosing, prognosing, monitoring, treating and/or preventing a hemopoietic malignancy and/or relapse thereof in a subject. In some embodiments, the methods can include determining an average cellular mass of cells in a sample from the subject and/or detecting one or more molecular signatures in one or more of the cells. In some embodiments, treatment includes administering one or more BCR-ABL tyrosine kinase inhibitors or a pharmaceutical formulation thereof, one or more pre-BCR signaling pathway inhibitors or a pharmaceutical formulation thereof, one or more p38 MAPK inhibitors or a pharmaceutical formulation thereof or any combination thereof.
    Type: Application
    Filed: October 30, 2020
    Publication date: May 6, 2021
    Inventors: Alexander K. Shalek, Peter Winter, David Weinstock, Mark Murakami, Scott Manalis, Andrew Navia, Jennyfer Galvez-Reyes
  • Publication number: 20200225239
    Abstract: Patient samples are monitored to detect minimal residual disease (MRD) post successful cancer treatment. Upon detection of MRD, functional assays can be performed on living cancer cells from the patient to evaluate possibly effective therapies along with subsequent genomic or other more destructive assays to provide additional efficacy information using a single sample. An effective treatment against the MRD can be identified and selected for the patient. The patient can be monitored and the process repeated until MRD can no longer be detected.
    Type: Application
    Filed: January 10, 2020
    Publication date: July 16, 2020
    Applicants: Massachusetts Institute of Technology, Dana-Farber Cancer Institute, Inc.
    Inventors: David Weinstock, Scott R. Manalis, Mark Murakami
  • Publication number: 20200224279
    Abstract: The invention provides methods for evaluating disease, such as cancer, by way of performing multiple assays involving single-cell analysis on live cells isolated from a sample of a patient. The data obtained from the multiple assays is analyzed and linked to thereby provide a characterization of any given cell having undergone analysis, which, in turn, allows for evaluation of the sample either known to be, or suspected of being, cancerous. A report may be generated based on the data analysis, wherein the report provides information related to the cancer evaluation, including, but not limited to, whether the sample tested positive for cancer, a determination of a stage or progression of cancer, and a customized treatment plan tailored to an individual patient's cancer diagnosis.
    Type: Application
    Filed: January 10, 2020
    Publication date: July 16, 2020
    Applicants: Massachusetts Institute of Technology, Dana-Farber Cancer Institute, Inc.
    Inventors: David Weinstock, Keith Ligon, Scott R. Manalis, Mark Murakami, Mark M. Stevens